Duchenne muscular dystrophy (DMD) is the most frequent and clinically most severe of the X linked muscular dystrophies. The underlying biochemical lesion is, however, still unresolved and much recent work has centred on localising and defining the defective gene locus, using several different molecular and cytogenetic mapping techniques. These studies have localised the DMD gene and also the gene for the milder Becker muscular dystrophy to the Xp2l region on the short arm of the X chromosome.
Cytogenetic analysis, using high resolution banding of prometaphase chromosomes, has indicated that various X chromosome rearrangements that involve the Xp2l region, including translocations and interstitial deletions, are responsible for the expression of the disease state. More than 12 different de novo X;autosomal translocations, each with an identifiable breakpoint within the Xp2l band, have been reported in isolated female patients exhibiting a Duchenne or Becker- control track, we have found it difficult to measure gene dosage reliably, especially when analysed by densitometry. It was for this reason that we initiated the analysis of pERT87 RFLP allele distribution in these deletion families. DNA 
POLYMORPHISMS
The various subclones of pERT87 show polymorphisms with several restriction enzymes and use of these has helped to identify those females hemizygous for the deletion. In fig 3 we have used a family previously examined by dosage analysis to demonstrate the inheritance of the deletion through the pedigree using the XmnI polymorphism with pERT87-15.
The obligate grandmother (I.2) is apparently homozygous for allele 1 and has passed this allele on to her normal son (11.4). However, both her daughters, II.5, a possible carrier, and 11.2, an obligate carrier, are apparently homozygous for Clinical histories of our nine deletion cases are unremarkable compared with the non-deleted subjects. None of the pERT87 or XJ1 1 deletion families showed a visible X chromosome deletion, apart from the single specially ascertained case mentioned previously.
The use of gene dosage and RFLP analysis within these deletion families has allowed conclusive identification of carrier females; prenatal diagnosis of N S T Thomas, P N Ray, R G Worton, and P S Harper affected males in these families is also now possible. In one family examined by both dosage and RFLP analysis, it can be confirmed retrospectively that the fetal DNA examined did not carry the deletion and that the male fetus would have been normal. Future prenatal diagnosis in such families will no longer have to rely on fetal sexing alone, nor on the use of linked probes with their inherent error rate.
For those families not showing a deletion, the use of polymorphisms at the pERT87 (DXS164) locus requires caution, since preliminary findings by ourselves and others suggest that recombination between these two loci has occurred and also because the Duchenne region of the X chromosome may be an area with a high frequency of recombination. Despite these reservations, the finding of two independently isolated DNA sequences sufficiently close to the Duchenne gene to show a molecular deletion in 5 to 10% of cases is a major advance, both towards isolation of the gene itself and in allowing prenatal diagnosis and carrier detection for the families concerned.
